文献速递妇科

依维莫司联合贝伐珠单抗治疗复发性卵巢、腹膜和输卵管癌的II期研究

Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer.
PubMed 文献 · Gynecol Oncol · 2019-11-15

这项开放标签、单中心II期试验纳入50例复发性卵巢、腹膜和输卵管癌患者,给予依维莫司10 mg/日口服联合贝伐珠单抗10 mg/kg静脉每14天一次(28天周期)。6个月无进展生存率为26%(校正后24%,95%CI 16.67-42.71%)。作者认为联合方案较单用贝伐珠单抗未明显改善缓解,但PI3K/mTOR通路改变的患者可能获益,需进一步研究。

要点

  • 6个月无进展生存率为26%(校正后24%,95%CI 16.67-42.71%)。
  • 1例完全缓解,6例部分缓解,35例最佳疗效为疾病稳定。
  • 25例患者发生2例4级和31例3级毒性,常见口腔黏膜炎、乏力、腹泻、高血压等。

核心结论

  • 依维莫司联合贝伐珠单抗较单用贝伐珠单抗未明显改善缓解,但PI3K/mTOR通路改变的选择性患者可能获益,需进一步研究。

研究设计与样本

  • 开放标签、单中心II期试验,纳入50例复发性卵巢、腹膜和输卵管癌患者,中位年龄60.5岁(范围28-82)。
  • 给药方案为依维莫司10 mg/日口服联合贝伐珠单抗10 mg/kg静脉每14天一次,28天为一周期,治疗持续至疾病进展或不良事件。

主要发现

  • 46例(92%)有可测量病灶;13例(26%,校正后24%)在6个月时无进展(95%CI 16.67-42.71%)。
  • 最佳疗效为1例完全缓解、6例部分缓解、35例疾病稳定。
  • 铂敏感和铂耐药患者均观察到缓解,部分既往接受过贝伐珠单抗者也观察到缓解。
  • 25例不同患者中记录到2例4级和31例3级毒性,常见毒性包括口腔黏膜炎、乏力、腹泻、高血压、疼痛、恶心和厌食。
  • 38例(76%)因疾病进展退出研究;长期缓解者中鉴定出独特的分子谱。

关键数值与推荐

  • 主要终点6个月无进展生存率为26%(校正后24%,95%CI 16.67-42.71%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recurrent ovarian, fallopian tube, and peritoneal cancers have limited potential for cure with traditional therapies. Preliminary results from a phase I study of everolimus and bevacizumab in advanced solid tumors showed it to be a promising combination. The primary objective of this study was to evaluate the 6-month progression-free survival for everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer. Secondary objectives included evaluation of efficacy and safety. METHODS: In this open-label, single-institution, phase II trial, patients received everolimus 10 mg/day by mouth and bevacizumab 10 mg/kg intravenously every 14 days on a 28-day cycle. Treatment continued until disease progression or adverse event. RESULTS: Fifty patients were enrolled. Median age was 60.5 years (range 28-82). Forty-six (92%) subjects had measurable disease. Thirteen (26%) (24% adjusted) were progression-free at 6 months (95% CI 16.67-42.71%). One patient had a complete response, while six had a partial response and 35 had stable disease as their best response. Patients with both platinum-sensitive and -resistant disease demonstrated responses, as did some prior bevacizumab exposure. There were two grade 4 and 31 grade 3 toxicities noted in 25 distinct patients. The most common reported toxicities included oral mucositis, fatigue, diarrhea, hypertension, pain, nausea and anorexia. Thirty-eight (76%) patients came off study because of disease progression. Unique molecular profiles were identified in long-term responders. CONCLUSIONS: Combining everolimus and bevacizumab does not distinctly improve response compared to bevacizumab alone, but further study of selected patients with alterations in the PI3K/mTOR pathway may document benefit.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Taylor SE, Chu T, Elvin JA, et al. Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer. Gynecol Oncol. 2019. PMID: 31739991. doi:10.1016/j.ygyno.2019.10.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。